Cancer treatments

CytoImmune Therapeutics Hosting Key Opinion Leader Webinar on Human Natural Killer (NK) Cell Immunotherapy

Retrieved on: 
Monday, July 19, 2021
Clinical medicine, Medicine, Branches of biology, Immune system, Virotherapy, Cancer immunotherapy, Cancer treatments, Lymphocytes, Immunotherapy, Natural killer cell, Fratricidins

MONROVIA, Calif., July 19, 2021 /PRNewswire/ -- CytoImmune Therapeutics , a clinical-stage immunotherapy company developing a novel class of NK cell-based therapies for cancer, announced today that it will host a key opinion webinar (KOL) on human natural killer (NK) cell immunotherapy on Monday, July 26at10 am Eastern Time.

Key Points: 
  • MONROVIA, Calif., July 19, 2021 /PRNewswire/ -- CytoImmune Therapeutics , a clinical-stage immunotherapy company developing a novel class of NK cell-based therapies for cancer, announced today that it will host a key opinion webinar (KOL) on human natural killer (NK) cell immunotherapy on Monday, July 26at10 am Eastern Time.
  • CytoImmune is currently developing an approach for human natural killer (NK) cell immunotherapy that involves an off-the-shelf CAR NK cell that enables the cell to recognize specific proteins or antigens that are present on the surface of tumor cells and is approaching the clinic in 2021 with lead target FLT-3 in AML.
  • CytoImmune Therapeutics is a clinical-stage biotechnology company developing a portfolio of natural killer (NK) immunotherapies designed to utilize the power of the patient's own immune system to eliminate cancer cells.
  • CytoImmune is moving towards filing the Investigational New Drug (IND) applications for novel immunotherapy programs in both solid and hematological malignancies.

Celsion Reports Data Safety Monitoring Board Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

Retrieved on: 
Monday, July 19, 2021
Clinical medicine, Cancer, Medicine, Cancer treatments, Oncology, Surgical oncology, Adjuvant therapy, Adjuvants, Analgesics, Ovarian cancer, Neoadjuvant therapy, Debulking

The OVATION 2 Study combines GEN-1, the Company's IL-12 gene-mediated immunotherapy, with standard-of-care neoadjuvant chemotherapy (NACT) in patients newly diagnosed with Stage III/IV ovarian cancer.

Key Points: 
  • The OVATION 2 Study combines GEN-1, the Company's IL-12 gene-mediated immunotherapy, with standard-of-care neoadjuvant chemotherapy (NACT) in patients newly diagnosed with Stage III/IV ovarian cancer.
  • NACT is designed to shrink the cancer as much as possible for optimal surgical removal after three cycles of chemotherapy.
  • Following NACT, patients undergo interval debulking surgery, followed by three additional cycles of chemotherapy to treat any residual tumor.
  • The Company also announced that more than 50% of the projected 110 patients have been enrolled in the OVATION 2 Study.

Scientific Article Covering Immune Modulating Interstitial Laser Thermotherapy by CLS’ Co-founder Professor Karl-Göran Tranberg Published in the Journal “Frontiers in Oncology”

Retrieved on: 
Monday, July 19, 2021
Medicine, Clinical medicine, Health care, Plasma physics, Interventional radiology, Cancer treatments, Cancer, Abscopal effect, Radiation therapy, Radiofrequency ablation, Laser ablation, Ablation

Physically based Local Destruction of Tumors (LDT) methods can induce immunologic effects and contribute to anti-tumor immune activity.

Key Points: 
  • Physically based Local Destruction of Tumors (LDT) methods can induce immunologic effects and contribute to anti-tumor immune activity.
  • The present review examined abscopal effects induced by presently available local destruction methods, such as radiofrequency ablation, focal laser ablation, cryotherapy and radiotherapy, without or with combination with immunotherapy.
  • The products are marketed for image-guided laser ablation and for treatment with imILT, the Company's interstitial laser thermotherapy with potential immunostimulatory effects.
  • CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B.

Scientific Article Covering Immune Modulating Interstitial Laser Thermotherapy by CLS’ Co-founder Professor Karl-Göran Tranberg Published in the Journal “Frontiers in Oncology”

Retrieved on: 
Monday, July 19, 2021
Medicine, Clinical medicine, Health care, Plasma physics, Interventional radiology, Cancer treatments, Cancer, Abscopal effect, Radiation therapy, Radiofrequency ablation, Laser ablation, Ablation

Physically based Local Destruction of Tumors (LDT) methods can induce immunologic effects and contribute to anti-tumor immune activity.

Key Points: 
  • Physically based Local Destruction of Tumors (LDT) methods can induce immunologic effects and contribute to anti-tumor immune activity.
  • The present review examined abscopal effects induced by presently available local destruction methods, such as radiofrequency ablation, focal laser ablation, cryotherapy and radiotherapy, without or with combination with immunotherapy.
  • The products are marketed for image-guided laser ablation and for treatment with imILT, the Company's interstitial laser thermotherapy with potential immunostimulatory effects.
  • CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B.

eFFECTOR Therapeutics Announces Publication of Tomivosertib Preclinical Data in Cell Reports

Retrieved on: 
Friday, July 16, 2021
Cancer treatments, Clinical medicine, Drugs, Breakthrough therapy, Orphan drugs, Cancer immunotherapy, Pembrolizumab, Lung cancer, Effector, Non-small-cell lung carcinoma, ATM serine/threonine kinase

This publication further validates the novel science on which eFFECTORs platform is built, said Steve Worland, Ph.D., president and CEO of eFFECTOR.

Key Points: 
  • This publication further validates the novel science on which eFFECTORs platform is built, said Steve Worland, Ph.D., president and CEO of eFFECTOR.
  • We are proud that our contributions have the potential to broaden the treatment landscape for those impacted by cancer.
  • Tomivosertib is being evaluated in KICKSTART, eFFECTORs randomized, double-blind, placebo-controlled Phase 2b study in non-small cell lung cancer (NSCLC) in combination with pembrolizumab.
  • Neither LWAC nor eFFECTOR gives any assurance that either LWAC or eFFECTOR or the combined company will achieve its expectations.

Bristol Myers Squibb Provides Update on CheckMate -651 Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Versus EXTREME Regimen as First-Line Treatment for Squamous Cell Carcinoma of the Head and Neck

Retrieved on: 
Friday, July 16, 2021
Stem cells, Biotechnology, Other Health, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Science, Clinical trials, Drugs, Clinical medicine, Cancer treatments, Orphan drugs, Antineoplastic drugs, Bristol-Myers Squibb, Breakthrough therapy, Cancer immunotherapy, Nivolumab, Ipilimumab, Renal cell carcinoma, Head and neck cancer

Squamous cell carcinoma of the head and neck (SCCHN) accounts for more than 90% of all head and neck cancers.

Key Points: 
  • Squamous cell carcinoma of the head and neck (SCCHN) accounts for more than 90% of all head and neck cancers.
  • OPDIVO (nivolumab), in combination with YERVOY (ipilimumab), is indicated for the treatment of patients with unresectable or metastatic melanoma.
  • OPDIVO (nivolumab), in combination with cabozantinib, is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC).
  • OPDIVO (nivolumab) is indicated for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy.

Advaxis to Present at the Non-Small Cell Lung Cancer Drug Development Summit

Retrieved on: 
Wednesday, July 14, 2021
Clinical medicine, Cancer treatments, Medicine, Cancer immunotherapy, Lung cancer, Antineoplastic drugs, Breakthrough therapy, Orphan drugs, Advaxis, Pembrolizumab, Merck & Co., Small-cell carcinoma

PRINCETON, N.J., July 14, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that Andres Gutierrez, M.D., Executive Vice President and Chief Medical Officer of Advaxis, will present data from Part B of the Companys Phase 1/2 study of ADXS-503 in combination with Pembrolizumab in patients with metastatic squamous or non-squamous non-small cell lung cancer at the virtual Non-Small Cell Lung Cancer Drug Development Summit on July 15th, 2021.

Key Points: 
  • PRINCETON, N.J., July 14, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that Andres Gutierrez, M.D., Executive Vice President and Chief Medical Officer of Advaxis, will present data from Part B of the Companys Phase 1/2 study of ADXS-503 in combination with Pembrolizumab in patients with metastatic squamous or non-squamous non-small cell lung cancer at the virtual Non-Small Cell Lung Cancer Drug Development Summit on July 15th, 2021.
  • Advaxis, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Lm-based antigen delivery products.
  • These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins.
  • KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.,Kenilworth, N.J., USA.

KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery Showed Statistically Significant Event-Free Survival (EFS) Result Versus Neoadjuvant Chemotherapy Alone in High-Risk Early-Stage TNBC

Retrieved on: 
Thursday, July 15, 2021
Other Health, Research, General Health, Pharmaceutical, Oncology, Infectious diseases, Clinical trials, Science, Biotechnology, FDA, Other Science, Health, Clinical medicine, Health sciences, Cancer treatments, Orphan drugs, Breakthrough therapy, Antineoplastic drugs, Cancer immunotherapy, Pembrolizumab, Adjuvant therapy, Neoadjuvant therapy, Therapy, Programmed cell death protein 1, Triple-Negative Breast Cancer (TNBC), Merck, TRIPLE-NEGATIVE BREAST CANCER (TNBC), MERCK

This is the first time an anti-PD-1/L1 therapy has demonstrated a statistically significant EFS result as combined neoadjuvant and adjuvant therapy for these patients.

Key Points: 
  • This is the first time an anti-PD-1/L1 therapy has demonstrated a statistically significant EFS result as combined neoadjuvant and adjuvant therapy for these patients.
  • KEYNOTE-522 was designed to study whether the combined neoadjuvant and adjuvant regimen with KEYTRUDA could help treat the cancer earlier.
  • Immune-mediated AEs led to death in 0.3% of patients receiving the KEYTRUDA regimen (n=2) and no patients receiving the chemotherapy-placebo regimen.
  • KEYTRUDA, as a single agent, is indicated for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy.

Vascular Disrupting Agents Markets, 2021-2030: Indications, Therapeutic Area, Molecules, Therapy, Route of Administration, and Regions - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 15, 2021
Pharmaceutical, Health, Cardiology, Cancer treatments, Vascular-targeting agent, Cancer

The "Vascular Disrupting Agents Market, 2021-2030: Indications, Therapeutic Area, Molecules, Therapy, Route of Administration, and Regions" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Vascular Disrupting Agents Market, 2021-2030: Indications, Therapeutic Area, Molecules, Therapy, Route of Administration, and Regions" report has been added to ResearchAndMarkets.com's offering.
  • The 'Vascular Disrupting Agents Market, 2021-2030 report features an extensive study of the current and future potential of vascular disrupting agents, being developed for the treatment of various types of cancer.
  • One of the key objectives of the report was to estimate the existing market size and the future opportunity associated with vascular disrupting agents, over the next decade.
  • Detailed profiles of the prominent players in this domain (shortlisted on the basis of number of vascular disrupting agents in development pipeline).

City of Hope and Osel Announce Exclusive License for Intellectual Property on the Use of Live Biotherapeutic Product CBM588 for Oncology Therapeutic Applications

Retrieved on: 
Wednesday, July 14, 2021
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Drugs, Cancer treatments, Clinical medicine, Bristol-Myers Squibb, Breakthrough therapy, Orphan drugs, Antineoplastic drugs, Ipilimumab, Nivolumab, Renal cell carcinoma, Pembrolizumab, Atezolizumab, Osel Inc., City of Hope, Miyarisan, OSEL INC., CITY OF HOPE, MIYARISAN

The experimental treatment was evaluated in a City of Hope investigator-initiated Phase 1b trial.

Key Points: 
  • The experimental treatment was evaluated in a City of Hope investigator-initiated Phase 1b trial.
  • 4513 titled First results of a randomized phase IB study comparing nivolumab/ipilimumab with or without CBM588 in patients with metastatic renal cell carcinoma is available here .
  • We look forward to working with City of Hope to further investigate how CBM588 can improve the lives of cancer patients.
  • Founded in 1913, City of Hope is a leader in bone marrow transplantation and immunotherapy such as CAR T cell therapy .